

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated December 3, 2018 (the “**Prospectus**”) issued by WUXI APPTEC CO., LTD.* 無錫藥明康德新藥開發股份有限公司 (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares.

This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). The information contained herein does not, and does not intend to, constitute an offer to sell or an invitation or solicitation of an offer to buy or subscribe for the securities of the Company in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.



WUXI APPTEC CO., LTD.*

無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock Code: 2359)

**PARTIAL EXERCISE OF
THE OVER-ALLOTMENT OPTION,
STABILIZING ACTIONS AND END OF
STABILIZATION PERIOD**

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Global Coordinators, on behalf of the International Underwriters, on January 4, 2019, in respect of an aggregate of 5,321,200 H Shares (the “**Over-allotment Shares**”), representing approximately 4.57% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option to cover over-allocations in the International Offering.

The Over-allotment Shares will be issued and allotted by the Company at HK\$68.0 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on January 5, 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by Morgan Stanley Asia Limited, as stabilizing manager (the “**Stabilizing Manager**”) or any person acting for it before and during the stabilization period were:

- (1) over-allocations of an aggregate of 17,471,100 H Shares in the International Offering, representing approximately 15.00% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (2) successive purchases of an aggregate of 12,149,900 H Shares in the price range of HK\$64.95 to HK\$68.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) on the market during the stabilization period. The last purchase made by the Stabilizing Manager on the market during the stabilization period was on January 4, 2019 at the price of HK\$66.95 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%); and
- (3) the partial exercise of the Over-allotment Option by the Joint Global Coordinators, on behalf of the International Underwriters, on January 4, 2019 in respect of 5,321,200 H Shares, representing approximately 4.57% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price of HK\$68.0 per Offer Share (exclusive of brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) to cover the over-allocations under the International Offering.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Global Coordinators, on behalf of the International Underwriters, on January 4, 2019, in respect of an aggregate of 5,321,200 H Shares, representing approximately 4.57% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option to cover over-allocations in the International Offering.

The Over-allotment Shares will be issued and allotted by the Company at HK\$68.0 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

The portion of the Over-allotment Option which has not been exercised by the Joint Global Coordinators (on behalf of the International Underwriters) lapsed on January 5, 2019.

Approval of Listing

Approval for the listing and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Hong Kong Stock Exchange. Listing of and dealings in such Over-allotment Shares are expected to commence on the Main Board of the Hong Kong Stock Exchange at 9:30 a.m. on January 9, 2019.

Share Capital upon the Partial Exercise of Over-allotment Option

The shareholding structure of the Company immediately before and immediately after the completion of the partial exercise of the Over-allotment Option is as follows:

	Immediately before the partial exercise of the Over-allotment Option		Immediately after the partial exercise of the Over-allotment Option	
	Number of Shares	Approximate percentage of the Company's issued share capital	Number of Shares	Approximate percentage of the Company's issued share capital
A Shares	1,048,266,886	90.00%	1,048,266,886	89.59%
H Shares issued under the Global Offering	<u>116,474,200</u>	<u>10.00%</u>	<u>121,795,400</u>	<u>10.41%</u>
Total	<u>1,164,741,086</u>	<u>100.00%</u>	<u>1,170,062,286</u>	<u>100.00%</u>

Use of Proceeds

The additional net proceeds of approximately HK\$352.8 million to be received by the Company from the issue and allotment of the Over-allotment Shares after deducting the underwriting commissions and other estimated expenses in connection with the partial exercise of the Over-allotment Option, will be used by the Company for the purposes as set out in the section headed "Future Plans and Use of Proceeds — Use of Proceeds" in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on January 5, 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by the Stabilizing Manager or any person acting for it before and during the stabilization period were:

- (1) over-allocations of an aggregate of 17,471,100 H Shares in the International Offering, representing approximately 15.00% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);

- (2) successive purchases of an aggregate of 12,149,900 H Shares in the price range of HK\$64.95 to HK\$68.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) on the market during the stabilization period. The last purchase made by the Stabilizing Manager on the market during the stabilization period was on January 4, 2019 at the price of HK\$66.95 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%); and
- (3) the partial exercise of the Over-allotment Option by the Joint Global Coordinators, on behalf of the International Underwriters, on January 4, 2019 in respect of 5,321,200 H Shares, representing approximately 4.57% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price of HK\$68.0 per Offer Share (exclusive of brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) to cover the over-allocations under the International Offering.

PUBLIC FLOAT

The Company has applied, and the Stock Exchange has granted, a waiver from strict compliance with the requirements of Rule 8.08(1)(b) of the Listing Rules subject to conditions imposed by the Stock Exchange.

Immediately after the issue and allotment of the Over-allotment Shares, the number of H Shares in public hands represents approximately 10.41% of the total issued share capital of the Company, which satisfies the minimum percentage prescribed in the conditions imposed in the waiver granted by the Hong Kong Stock Exchange from strict compliance with Rule 8.08(1)(b) of the Hong Kong Listing Rules.

By order of the Board of Directors
WuXi AppTec Co., Ltd.
Dr. Ge Li
Chairman

Hong Kong, January 6, 2019

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*